Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19812708 | 1.00 | AOC3 (0.37) | AOC3SLC1A3SLC1A2SLC1A1IRAK4 | |
| SCHEMBL18787634 | 1.00 | AOC3 (0.37) | AOC3SLC1A3SLC1A2SLC1A1IRAK4 | |
| SCHEMBL18787795 | 1.00 | AOC3 (0.37) | AOC3SLC1A3SLC1A2SLC1A1IRAK4 | |
| SCHEMBL19119024 | 0.80 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1PDE4D | |
| SCHEMBL3387724 | 0.79 | AOC3 (0.34) | AOC3IRAK4GRM5ACACBACACA | |
| SCHEMBL21429865 | 0.78 | IRAK4 (0.35) | AOC3IRAK4ACACBACACAPIK3CD | |
| SCHEMBL12689563 | 0.78 | IRAK4 (0.35) | AOC3IRAK4ACACBACACAPIK3CD | |
| SCHEMBL18050578 | 0.77 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18787702 | 0.76 | AOC3 (0.32) | AOC3IRAK4GRM5ACACBACACA | |
| SCHEMBL18787730 | 0.76 | AOC3 (0.32) | AOC3IRAK4GRM5ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3149001-B1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | AOC3 2582/4885SLC1A3 3917/4885SLC1A2 4562/4885 |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | AOC3 2582/4885SLC1A3 3917/4885SLC1A2 4562/4885 |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | FBP1, MMEL1, MALT1 | AOC3 2246/4885SLC1A3 4100/4885SLC1A2 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.